Form 4: Xenon Director Steven Gannon Exercises Stock Options

Director Steven Gannon acquired 3,500 common shares of Xenon Pharmaceuticals through the exercise of stock options at $7.38 per share.

Summary

• Steven Gannon, a Director at Xenon Pharmaceuticals, exercised stock options for 3,500 shares on May 12, 2026.
• The exercise price for these options was $7.38 per share.
• Following this transaction, Gannon's direct ownership of common shares increased to 10,641.
• The options were fully vested and exercisable at the time of the transaction.
• The options were exercised shortly before their expiration date of June 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as the director is increasing his direct ownership by exercising options shortly before their expiration without an accompanying sale.

Positives

• The director increased his direct equity stake in the company.
• The exercise of options demonstrates a continued commitment to the company by a member of the board.
• The transaction was a direct acquisition of shares rather than a 'cashless' exercise followed by an immediate sale.

Negatives

• No negative factors were identified in this routine regulatory transaction report.

Risks

• No specific business or financial risks were disclosed in this Form 4 filing.

Future Outlook

No forward-looking guidance or strategic updates were provided in this transaction report.

Management Comments

• No management comments or statements were included in this regulatory filing.

Industry Context

StockSavvy.ai notes that insider option exercises are standard practice in the biotechnology sector, often used as a mechanism for directors to increase their equity positions or realize compensation value as options approach their expiration dates.

Comparison to Industry Standards

• The exercise of 3,500 shares is consistent with director-level equity management seen at peer biotechnology firms such as Neurocrine Biosciences and Sage Therapeutics.
• The retention of shares following exercise is generally viewed more favorably by the market than an immediate sale of the acquired shares.

Related Party Transactions

• Steven Gannon, a director, exercised options granted by the company to acquire 3,500 common shares at a set exercise price of $7.38.

Stakeholder Impact

• Minimal impact on shareholders due to the small volume of shares relative to the total market capitalization.
• Positive signal to employees and investors regarding board member confidence.

Next Steps

• No future actions or milestones were mentioned in the filing.

Key Dates

Recommendation

The transaction is a routine insider option exercise that does not signal a material change in company fundamentals or strategic direction.

Keywords

Xenon Pharmaceuticals, XENE, Insider Trading, Stock Options, Steven Gannon, Biotechnology, SEC Form 4